Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;54(5):515-23.
doi: 10.1097/qai.0b013e3181e3a70e.

Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi

Sherry L Farr  1 , Julie A E Nelson, Thokozani J Ng'ombe, Athena P Kourtis, Charles Chasela, Jeffrey A Johnson, Angela D M Kashuba, Gerald L Tegha, Jeffrey Wiener, Joseph J Eron, Harriet N Banda, Mwanangwa Mpaso, Jonathan Lipscomb, Chrissie Matiki, Susan A Fiscus, Denise J Jamieson, Charles van der Horst; BAN Study Team
Collaborators, Affiliations

Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi

Sherry L Farr et al. J Acquir Immune Defic Syndr. 2010 Aug.

Erratum in

  • J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e53

Abstract

Background: We assessed whether 7 days of zidovudine + lamivudine postpartum with single-dose nevirapine at labor decreases nevirapine resistance in HIV-infected women in Malawi.

Methods: HIV-infected pregnant women receiving intrapartum single-dose nevirapine and 7 days of zidovudine + lamivudine (n = 132) and women receiving intrapartum single-dose nevirapine alone (n = 66) were followed from an antenatal visit through 6 weeks postpartum. Plasma specimens at 2 and 6 weeks postpartum were tested for genotypic resistance to nevirapine by population sequencing and sensitive real-time polymerase chain reaction. Poisson regression was used to determine predictors of postpartum nevirapine resistance.

Results: Median HIV RNA was similar at entry (4.27 log vs. 4.35 log, P = 0.87), differed at 2 weeks postpartum (2.67 log vs. 3.58 log, P < 0.0001) but not at 6 weeks postpartum (4.49 log vs. 4.40 log, P = 0.79), between single-dose nevirapine/zidovudine + lamivudine and single-dose nevirapine groups, respectively. Nevirapine resistance, measured by population sequencing and sensitive real-time polymerase chain reaction, was significantly less common in those receiving single-dose nevirapine/zidovudine + lamivudine compared with single-dose nevirapine, respectively, at 2 weeks [10% (4 of 40) vs. 74% (31 of 42), P < 0.0001] and 6 weeks postpartum [10% (11 of 115) vs. 64% (41 of 64), P < 0.0001; adjusted relative risk = 0.18, 95% confidence interval (0.10 to 0.34)].

Conclusions: The significant decrease in nevirapine resistance conferred by 1 week of zidovudine + lamivudine should help policymakers optimize peripartum HIV prophylaxis recommendations.

Trial registration: ClinicalTrials.gov NCT00164762.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Median viral load† and percent of women with detectable nevirapine‡ (NVP) by drug regimen among HIV-infected mothers*, Lilongwe, Malawi
*Among women with testable plasma specimens at 2 weeks (sdNVP: n=45; sdNVP/ZDV+3TC: n=53) and 6 weeks postpartum (sdNVP: n=65; sdNVP/ZDV+3TC: n=120); †Chi square p-value for viral load: antenatal: p=0.87; 2 weeks postpartum: p<0.0001, 6 weeks postpartum: p=0.79 ‡Chi square p-value for NVP concentration: delivery: p=0.47; 2 weeks postpartum: p<0.0001; 6 weeks postpartum: p=0.79
Figure 2
Figure 2. Prevalence of NVP resistance mutations by drug regimen among HIV-infected mothers*, Lilongwe, Malawi
*Among women with testable plasma specimens at 2 weeks (sdNVP: n=45; sdNVP/ZDV+3TC: n=53) and 6 weeks postpartum (sdNVP: n=65; sdNVP/ZDV+3TC: n=120) and no NVP resistance at an antenatal visit
See this image and copyright information in PMC

References

    1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802. - PubMed
    1. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859–868. - PubMed
    1. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005;192:30–36. - PubMed
    1. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS. 2005;19:2167–2169. - PubMed
    1. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007;195:711–715. - PubMed

Publication types

MeSH terms

Associated data